OncoBeta- A Pioneer and Innovator in the Epidermal Radioisotope Therapy sector
Skin is the largest organ of the body and represents the first barrier between the inside of the body and external influences like mechanical stress or radiation for example. However, long-term influences on the skin might lead to irreparable damage that can develop into skin cancer e.g. Non-Melanocytic Skin Cancer (NMSC). NMSC is the world’s most common type of cancer. 90% of NMSC cases are seen on the face or head. In most cases, NMSC is not fatal, but if left untreated, it can destroy local tissue and also cause disfigurement or dysfunction, which impairs quality of life.
OncoBeta
Innovating in this field, to provide painless and easy treatment solutions is OncoBeta. Headquartered in Garching Technology and Founders Center GATE near Munich, OncoBeta is a privately held medical device company. They specialize in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s), and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy).
OncoBeta’s primary aim is to improve patient experiences, patient outcomes, and patient expectations while redefining the approach to treating NMSC Patients suffering from NMSCs are often left with standard care options, which are either painful, non-aesthetically desired, or are invasive procedures in nature. OncoBeta is part of the story trying to rectify this.
OncoBeta’s flagship therapy the Rhenium-SCT® is specialized state-of-the-art brachytherapy utilizing the radioisotope Rhenium-188, which in this case is used for the treatment of the most common types of NMSC called basal and squamous cell carcinomas.
Rhenium-188 is a so-called beta-emitter isotope with excellent therapeutic advantages. Rhenium-188 has a half-life of about 17 hours which means that it decays continuously while mainly emitting beta-radiation. The penetration range of Rhenium-188’s beta-radiation in human tissue is up to 3mm in depth. This makes Rhenium-188 ideal for targeted treatment of superficial skin cancer types, like most non-melanoma skin cancers. The main objective of the Rhenium-SCT® is to be a painless, personalized, non-invasive therapy targeting and destroying cancer cells in the area needed to treat.
The Rhenium-SCT is a CE-certified method arising from over 10 years of experience and clinical studies (>460 patients, >1300 lesions). It provides NMSC patients with a single-session, painless, highly-effective non-surgical treatment with excellent aesthetic results and complete remissions in up to 98,5% of all cases.
With their innovative therapy the Rhenium-SCT®, they provide a scalable, highly effective, clinically proven, easy, and comfortable solution for NMSC patients, which improves overall patient outcomes and experiences.
When it is about treating a disease like cancer, there are many challenges to be met. One of the biggest challenges for OncoBeta is disrupting the standard care and its referral network to provide patients with the therapeutic solution and the outcomes they deserve. NMSC treatment is characterized by inefficiencies. Long referral chains, endowed interests, lack of patient focus, and apprehension to innovation are some of the more pronounced inefficiencies characterizing the treatment of NMSCs. Ultimately, the last one in focus given these difficulties is the patient.
OncoBeta is fighting from inside the healthcare apparatus to offer a better alternative for those suffering from NMSCs. This means being highly active in the NMSC therapeutic community, exchanging dialogues to broaden the perspectives of clinicians about standard care and other therapeutic alternatives, such as the Rhenium-SCT®.
OncoBeta is characterized by innovations in the treatments they provide. Their uniqueness and forward-thinking set them apart from everyone else. OncoBeta is bringing modern technology and innovation to the market today. They have gone a different direction in the treatment of non-melanocytic skin cancers than the current standard therapies. The Rhenium-SCT® offers everything that patients and physicians are asking for, a painless, non-invasive, personalized, single-session treatment with excellent clinical and aesthetic results.
OncoBeta maintains the highest radioactive safety requirements in conformity with all health, safety, and environmental protection regulatory standards to ensure maximum security for the patient and health care provider. Their products are produced under strict specifications meeting international guidelines to deliver the highest quality possible.
“An efficient, dedicated and passionate team makes it all happen.” states Shannon D. Brown III, CEO and Managing Director of OncoBeta“ The team works relentlessly to improve NMSC patients` treatment and to increase our current therapeutic portfolio, while constantly striving to develop additional non-invasive therapies in the areas of dermatology and oncology for patients in need.”
“The working mentality at OncoBeta is both very effective and simple “You can’t fix something if you don’t know what is broken.” says Shannon D. Brown III “If something isn’t going right or won’t work the way you thought, someone needs to tell you no matter who that is. We treat each other with the same dignity and respect that we expect and would like to receive.”
The Rhenium-SCT® is presently available in Germany, Italy, Australia, and South Africa. To take it a step further, and introduce patient-personalized brachytherapy, OncoBeta is anticipating expansionary activities in other European/ Non-European countries such as France, United Kingdom, Spain, Austria, Switzerland, Scandinavian Countries, Canada, United States, SE Asia, and Brazil scheduled over the next 2-3 years. OncoBeta is also currently evaluating further exciting applications and treatment possibilities with Rhenium.
